Business
TriSalus Life Sciences Reports Q4 and Full Year 2024 Financial Results and Provides Business Update
DENVER, March 27, 2025--TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announced its financial results for the fourth quarter and full year
About this update from Trisalus Life Sciences, Inc.
[{"type":"list","items":[{"val":[{"type":"text","content":"Revenues of $8.3 Million in Q4 and $29.4 Million for Full-Year 2024, Representing Growth of 44% And 59%, Respectively, Versus the Prior Year Periods","length":148,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":148,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Gross Margin of 85% and 86% for Q4 and Full-Year 2024","length":53,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":53,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Reaffirmed 2025 Guidance of Greater than 50% Revenue Growth, Greater than 20% Reduction in Operating Expenses, Positive EBITDA, and Positive Cash flow in H2 2025","length":161,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":161,"olType":false},{"type":"list","items":[{"val":[{"type":"text","content":"Management to host earnings conference call on March 27 at 8:00 a.m. EDT","length":72,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":72,"olType":false},{"type":"text","content":"DENVER, March 27, 2025--(BUSINESS WIRE)--TriSalus Life Sciences Inc., (Nasdaq: TLSI), oncology focused medical technology business seeking to transform outcomes for patients with solid tumors by integrating our innovative delivery technology with standard-of-care therapies, and with our investigational immunotherapeutic, nelitolimod, a class C Toll-like receptor 9 agonist, for a range of different therapeutic and technology applications, today announced its financial results for the fourth quarter and full year ended December 31, 2024, and provided a business update.","length":573,"tagName":"p"},{"type":"text","content":""We achieved commercial and clinical progress throughout 2024, and positioning TriSalus for greater success in 2025," said Mary Szela, President and Chief Executive Officer of TriSalus Life Sciences. "We achieved $29.4 million in total revenue, marking 59% growth year-over-year, and continue to expect to deliver greater than 50% revenue growth in 2025. Additionally, we anticipate reducing operating expenses by more than 20%, achieving positive EBITDA for the full year, and achieving positive cash flow in the second half of the year."","length":559,"tagName":"p"},{"type":"text","content":""We were also pleas...